Released Sep 16, 2024, after the close
10-Q filed Sep 16, 2024, 47 days after period end · 0001654954-24-011967
Q3 2024 · 10-Q
Revenue$2.42M$2.42M −47.2% vs Q3 2023+1.7% vs Q2 2024
Net Income-$309.19K-$309.19K N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted$0.01$0.01 no prior Q3 2023 on fileN/M vs Q2 2024
Gross Profit$635,384−59.0%
Operating Income-$381,782N/M
Operating Cash Flow-$670,327N/M
Free Cash Flowderived-$672,235N/M
Margins · derived
Gross margin26.3%−7.6 pt vs Q3 2023
Operating margin-15.8%−25.8 pt vs Q3 2023
Net margin-12.8%−24.3 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $2.42M | $4.58M | $4.77M | $4.99M |
| Net Income | -$309.19K | $526.24K | $288.03K | $2.28M |
| EPS Diluted | $0.01 | — | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR